These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1414226)

  • 1. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.
    Benítez J; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Ladero JM
    J Neurol Sci; 1993 Jul; 117(1-2):8-11. PubMed ID: 8410072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
    J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 7. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine hydroxylation in a Polish population.
    Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
    Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Narcotic analgesics and debrisoquine polymorphism.
    Lavrijsen KL; Heykants JJ
    Anesthesiology; 1989 Sep; 71(3):474-5. PubMed ID: 2570539
    [No Abstract]   [Full Text] [Related]  

  • 12. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Barbeau A; Cloutier T; Roy M; Plasse L; Paris S; Poirier J
    Lancet; 1985 Nov; 2(8466):1213-6. PubMed ID: 2866293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN; Bentué-Ferrer D; Brunet-Bourgin F; Morel G; Allain H
    Presse Med; 1990 May; 19(20):947-9. PubMed ID: 2141131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
    Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
    Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
    Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
    FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.